The US Food and Drug Administration (FDA) has approved Merck’s Juvisync, a once-daily therapy for type 2 diabetes that combines glucose-lowering medication sitagliptin, the active component of Januvia, with cholesterol-lowering medication simvastatin.
The approval is based upon clinical bioequivalence studies in healthy subjects, which demonstrated that the administration of Juvisync is equivalent to the co-administration of corresponding doses of the two individual medications as separate tablets.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Juvisync will enable healthcare providers to help patients who need the blood sugar-lowering benefits of a dipeptidyl peptidase-4 inhibitor and the cholesterol-lowering benefits of simvastatin with the convenience of a single tablet once daily.
However, the therapy should be discontinued immediately if markedly elevated creatine phosphokinase levels occur or myopathy is diagnosed or suspected, the company said.
